Пузырчатка

Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1900-13.Полный текст  Аннотация

Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus. Nat Rev Dis Primers. 2017 May 11;3:17026. Аннотация

Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts. J Am Acad Dermatol. 2020 Mar;82(3):575-85.e1. Аннотация

Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017 May 20;389(10083):2031-40. Аннотация

1. Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1900-13.Полный текст  Аннотация

2. Hsu YM, Fang HY, Lin CL, et al. The risk of depression in patients with pemphigus: a nationwide cohort study in Taiwan. Int J Environ Res Public Health. 2020 Mar 17;17(6):1983.Полный текст  Аннотация

3. Sajda T, Sinha AA. Autoantibody signaling in pemphigus vulgaris: development of an integrated model. Front Immunol. 2018;9:692.Полный текст  Аннотация

4. Mutasim DF, Pelc NJ, Anhalt GJ. Paraneoplastic pemphigus. Dermatol Clin. 1993 Jul;11(3):473-81. Аннотация

5. Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus. Nat Rev Dis Primers. 2017 May 11;3:17026. Аннотация

6. Simon DG, Krutchkoff D, Kaslow RA, et al. Pemphigus in Hartford County, Connecticut, from 1972 to 1977. Arch Dermatol. 1980 Sep;116(9):1035-7. Аннотация

7. Porro AM, Seque CA, Ferreira MCC, et al. Pemphigus vulgaris. An Bras Dermatol. 2019 Jul 29;94(3):264-78.Полный текст  Аннотация

8. Alpsoy E, Akman-Karakas A, Uzun S. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid. Arch Dermatol Res. 2015 May;307(4):291-8.Полный текст  Аннотация

9. Jelti L, Cordel N, Gillibert A, et al. Incidence and mortality of pemphigus in France. J Invest Dermatol. 2019 Feb;139(2):469-73.Полный текст  Аннотация

10. Lee YB, Lee JH, Lee SY, et al. Incidence and death rate of pemphigus vulgaris and pemphigus foliaceus in Korea: a nationwide, population-based study (2006-2015). J Dermatol. 2018 Dec;45(12):1396-1402. Аннотация

11. Försti AK, Vuorre O, Laurila E, et al. Pemphigus foliaceus and pemphigus erythematosus are the most common subtypes of pemphigus in Northern Finland. Acta Derm Venereol. 2019 Nov 1;99(12):1127-30. Аннотация

12. Wertenteil S, Garg A, Strunk A, et al. Prevalence Estimates for Pemphigus in the United States: A Sex- and Age-Adjusted Population Analysis. JAMA Dermatol. 2019 May 1;155(5):627-629.Полный текст  Аннотация

13. Hans-Filho G, dos Santos V, Katayama JH, et al. An active focus of high prevalence of fogo selvagem on an Amerindian reservation in Brazil. Cooperative Group on Fogo Selvagem Research. J Invest Dermatol. 1996 Jul;107(1):68-75. Аннотация

14. Ohzono A, Sogame R, Li X, et al. Clinical and immunological findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol. 2015 Dec;173(6):1447-52. Аннотация

15. Leger S, Picard D, Ingen-Housz-Oro S, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol. 2012 Oct;148(10):1165-72.Полный текст  Аннотация

16. Becker BA, Gaspari AA. Pemphigus vulgaris and vegetans. Dermatol Clin. 1993 Jul;11(3):429-52. Аннотация

17. Crosby DL, Diaz LA. Endemic pemphigus foliaceus. Fogo selvagem. Dermatol Clin. 1993 Jul;11(3):453-62. Аннотация

18. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus - an autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990 Dec 20;323(25):1729-35.Полный текст  Аннотация

19. Diaz LA, Sampaio SA, Rivitti EA, et al. Endemic pemphigus foliaceus (fogo selvagem): II. Current and historical epidemiological aspects. J Invest Dermatol. 1989;92:4-12. Аннотация

20. Vernal S, Pepinelli M, Casanova C, et al. Insights into the epidemiological link between biting flies and pemphigus foliaceus in southeastern Brazil. Acta Trop. 2017 Dec;176:455-62. Аннотация

21. Aoki V, Millikan RC, Diaz LA, et al. Environmental risk factors in pemphigus foliaceus (fogo selvagem). J Investig Dermatol Symp Proc. 2004;9:34-40. Аннотация

22. Qian Y, Jeong JS, Maldonado M, et al. Brazilian pemphigus foliaceus anti-desmoglein 1 autoantibodies cross-react with sand fly salivary LJM11 antigen. J Immunol. 2012 Aug 15;189(4):1535-9.Полный текст  Аннотация

23. Peng B, Temple BR, Yang J, et al. Identification of a primary antigenic target of epitope spreading in endemic pemphigus foliaceus. J Autoimmun. 2021 Jan;116:102561. Аннотация

24. Harman KE, Gratian MJ, Bhogal BS, et al. A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype. Br J Dermatol. 2000 Aug;143(2):343-8. Аннотация

25. Craft J, Fatenejad S. Self antigens and epitope spreading in systemic autoimmunity. Arthritis Rheum. 1997 Aug;40(8):1374-82. Аннотация

26. Billet SE, Grando SA, Pittelkow MR. Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity. 2006 Nov;39(7):617-30. Аннотация

27. Bordenave K, Griffith J, Hordes SM, et al. The historical and geomedical immunogenetics of pemphigus among the descendants of Sephardic Jews in New Mexico. Arch Dermatol. 2001 Jun;137(6):825-6. Аннотация

28. Brenner S, Goldberg I. Drug-induced pemphigus. Clin Dermatol. Jul-Aug 2011;29(4):455-7. Аннотация

29. Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts. J Am Acad Dermatol. 2020 Mar;82(3):575-85.e1. Аннотация

30. Raneses E, McGinley Simpson M, Rosenberg A, et al. A retrospective review of autoimmune bullous disease antibody positivity before clinical symptoms. J Am Acad Dermatol. 2021 Feb 4;S0190-9622(21)00315-7. Аннотация

31. Harman KE, Brown D, Exton LS, et al. British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol. 2017 Nov;177(5):1170-1201.Полный текст  Аннотация

32. Nousari HC, Deterding R, Wojtczack H, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med. 1999 May 6;340(18):1406-10. Аннотация

33. Cummins DL, Mimouni D, Tzu J, et al. Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies. J Am Acad Dermatol. 2007 Jan;56(1):153-9. Аннотация

34. Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017 May 20;389(10083):2031-40. Аннотация

35. Wang HH, Liu CW, Li YC, et al. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015 Nov;95(8):928-32.Полный текст  Аннотация

36. Tavakolpour S, Mahmoudi H, Balighi K, et al. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review. Int Immunopharmacol. 2018 Jan;54:131-8. Аннотация

37. Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019 Sep 7;394(10201):882-94. Аннотация

38. Beissert S, Mimouni D, Kanwar AJ, et al. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. 2014 Dec;150(12):1331-5. Аннотация

39. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006 Nov;142(11):1447-54. Аннотация

40. Kawashita MY, Tsai K, Aoiki V, et al. Mycophenolate mofetil as an adjuvant therapy for classic and endemic pemphigus foliaceus. J Dermatol. 2005 Jul;32(7):574-80. Аннотация

41. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007 Aug 9;357(6):545-52.Полный текст  Аннотация

42. Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006 Oct 26;355(17):1772-9.Полный текст  Аннотация

43. Gurcan HM, Jeph S, Ahmed AR, et al. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety. Am J Clin Dermatol. 2010;11(5):315-26. Аннотация

44. Behzad M, Möbs C, Kneisel A, et al. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol. 2012 Apr;166(4):844-52. Аннотация

45. Frew JW, Murrell DF. Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome). Dermatol Clin. 2011 Oct;29(4):607-12. Аннотация

46. Czernik A, Camilleri M, Pittelkow MR, et al. Paraneoplastic autoimmune multiorgan syndrome: 20 years after. Int J Dermatol. 2011 Aug;50(8):905-14. Аннотация

47. Kardos M, Levine D, Gürcan HM, et al. Pemphigus vulgaris in pregnancy: analysis of current data on the management and outcomes. Obstet Gynecol Surv. 2009 Nov;64(11):739-49. Аннотация

48. Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol. 1996 Dec;132(12):1435-9. Аннотация

49. US Nation Library of Medicine. Open-label Study to Determine the Maximum Tolerated Dose of DSG3-CAART in Mucosal-dominant PV Patients (mPV). Jan 2021 [internet publication].Полный текст

50. Ren Z, Narla S, Hsu DY, et al. Association of serious infections with pemphigus and pemphigoid: analysis of the Nationwide Inpatient Sample. J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1768-76. Аннотация